[Physiopathology of hemostasis. Which advances are useful for the clinician?].
Progress made in the field of haemostasis 30 years ago was essentially to do with the identification of the different activators of coagulation, the deficits of which provoke hemorrhage. Over the last ten years, progress has been made which is of benefit to research into thrombosis. This wave of progress, still in its infancy, aids both the understanding of the mechanisms involved, and the treatment of thrombosis. The role of the deficits reducing coagulation in the occurrence of thromboses is the most distinctive if not unique, fact. The molecular study of the factors of coagulation constitutes another aspect of recent progress; this gives a better understanding of the pathological phenomena and anticoagulant behaviour. Examples are given of this progress in molecular study and in the aetiological diagnosis of thrombosis.
D000990:Antithrombin III / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D005174:Factor XII / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D011486:Protein C
D006023:Glycoproteins; D011486:Protein C; D000990:Antithrombin III; D005174:Factor XII
Physiopathologie de l'hémostase. Quels progrès utiles aux cliniciens?